
==== Front
Neurooncol Adv
Neurooncol Adv
noa
Neuro-Oncology Advances
2632-2498
Oxford University Press US

10.1093/noajnl/vdae090.067
vdae090.067
Final Category: Neuroimaging/Radiologic Advances
AcademicSubjects/MED00300
AcademicSubjects/MED00310
NIRL-06 IS THE PRESENCE OF NEOPLASTIC MENINGITIS ASSOCIATED WITH A WORSE PROGNOSIS IN REAL-WORLD PATIENTS WITH BREAST CANCER AND BRAIN METASTASES?
Cacho-Díaz Bernardo Instituto Nacional de Cancerología, Mexico City, Mexico

Cabrera Paula Instituto Nacional de Cancerología, Mexico City, Mexico

Arrieta Oscar Instituto Nacional de Cancerología, Mexico City, Mexico

8 2024
02 8 2024
02 8 2024
6 Suppl 1 2024 SNO/ASCO CNS Metastases Conference i21i21
© The Author(s) 2024. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
2024
https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Abstract

BACKGROUND

Central nervous system (CNS) metastases are a severe and frequent scenario in patients with breast cancer; CNS metastases can be divided into parenchymal metastases (brain metastases) or neoplastic meningitis (leptomeningeal disease). The occurrence of both in the same patient is a common picture but scantly reported.

OBJECTIVE

To measure the association of brain metastases with or without meningeal involvement in patients with breast cancer and brain metastases.

METHODS

A prospectively acquired database from patients with breast cancer and central nervous system metastases was retrospectively analyzed.

RESULTS

In 659 patients, 292 (44%) had brain metastases (BM), 169 (26%) had neoplastic meningitis (NM), and 198 (30%) had both (BM+NM). The median overall survival (MOS) in the whole cohort was 9.59 months (95%CI 8.0 – 11.2); in those with BM, the MOS was 12.2 months (95%CI 10 – 14.5); in the NM group, the MOS was 5.8 months (95%CI 4.3 – 7.2 months); and for those on the group with both BM and NM (BM+NM) the MOS was 10.3 months (95%CI 8.0 – 26.7), P <0.001. After statistical adjustment, the difference in survival between BM and BM+NM persisted.

CONCLUSION

The presence of meningeal involvement in patients with breast cancer and brain metastases is associated with a worse prognosis.
==== Body
pmc
